A naturopathic treatment approach for mild and moderate COVID-19: A retrospective chart review

被引:4
|
作者
Barber, Melissa S. [1 ]
Barrett, Richard [1 ]
Bradley, Ryan D. [1 ]
Walker, Erin [2 ]
机构
[1] Natl Univ Nat Med, Helfgott Res Inst, 2220 SW 1st Ave, Portland, OR 97201 USA
[2] Canby Clin, 452 NW 1st Ave, Canby, OR USA
基金
美国国家卫生研究院;
关键词
COVID-19; SARS-CoV-2; Herbal medicine; Phytotherapy; Vitamins; Minerals; Nutrition therapy; Orthomolecular therapy; Intravenous infusions; Immune system; Complementary therapies; Naturopathic medicine; Integrative medicine; Case reports; VITAMIN-C; ANTIMICROBIAL ACTIVITY; COMMON COLD; INFECTION; ISOALANTOLACTONE; METHODOLOGY; PREVENTION; EXTRACT; DISEASE; ZINC;
D O I
10.1016/j.ctim.2021.102788
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objectives: The coronavirus disease 2019 (COVID-19) pandemic has led to significant morbidity and mortality. Although COVID-19 vaccination is available, therapeutic options are still needed. The goal of the present manuscript is to report on a treatment strategy used in a naturopathic medical practice for mild and moderate COVID-19. Design: A retrospective chart review was conducted of 30 consecutive patients diagnosed with mild and moderate COVID-19 who were provided multi-nutrient, herbal, and probiotic treatment in a rural, out-patient, naturopathic primary care setting. Main outcomes measures: The primary outcome was treatment safety; secondary outcomes included changes in symptoms, progression to severe COVID-19, incidence of long COVID, and recovery time. Results: No side effects or adverse events were reported from treatment and all patients experienced resolution of symptoms presumed to be associated with COVID-19 infection. One patient who had been ill for 28 days prior to presentation was hospitalized. Five patients had an illness duration of more than one month. Time to treatment was correlated with duration of illness post-treatment (r = 0.63, p < 0.001) and more symptoms at presentation was correlated with a longer duration of illness (r = 0.52, p < 0.01). Conclusions: In this retrospective chart review, a multi-nutrient, herbal, and probiotic therapeutic approach for mild and moderate COVID-19 appeared to be well-tolerated. Delay in seeking treatment after symptom onset, as well as more symptoms at presentation, were correlated with a longer duration of illness. This treatment strategy may have clinical benefit, warranting prospective clinical trials with confirmed COVID-19 cases.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Kidney outcome after mild to moderate COVID-19
    Schmidt-Lauber, Christian
    Haenzelmann, Sonja
    Schunk, Stefan
    Petersen, Elina L.
    Alabdo, Ammar
    Lindenmeyer, Maja
    Hausmann, Fabian
    Kuta, Piotr
    Renne, Thomas
    Twerenbold, Raphael
    Zeller, Tanja
    Blankenberg, Stefan
    Fliser, Danilo
    Huber, Tobias B.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (09) : 2031 - 2040
  • [32] Neurological manifestations in mild and moderate cases of COVID-19
    Ghada Saed Abdel Azim
    Marwa Abdellah Osman
    [J]. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 57
  • [33] New Antiviral on the Horizon for Mild to Moderate COVID-19
    Harris, Emily
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (10): : 821
  • [34] Neurological manifestations in mild and moderate cases of COVID-19
    Azim, Ghada Saed Abdel
    Osman, Marwa Abdellah
    [J]. EGYPTIAN JOURNAL OF NEUROLOGY PSYCHIATRY AND NEUROSURGERY, 2021, 57 (01):
  • [35] Efficacy of early treatment with hydroxychloroquine in people with mild to moderate COVID-19: a systematic review and meta-analysis
    V. Hernandez, Adrian
    Ingemi, John, III
    Sherman, Michael
    Pasupuleti, Vinay
    Barboza, Joshuan J.
    Piscoya, Alejandro
    Roman, Yuani M.
    White, Michael
    [J]. ARCHIVES OF MEDICAL SCIENCE, 2022, 18 (04) : 939 - 948
  • [36] Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study
    Zhou, Zhiguo
    Zheng, He
    Xiao, Gui'e
    Xie, Xiangping
    Rang, Jiaxi
    Peng, Danhong
    [J]. BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [37] Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study
    Zhiguo Zhou
    He Zheng
    Gui’e Xiao
    Xiangping Xie
    Jiaxi Rang
    Danhong Peng
    [J]. BMC Infectious Diseases, 24
  • [38] Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study
    Park, Susin
    Je, Nam Kyung
    Kim, Dong Wan
    Park, Miran
    Heo, Jeonghun
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, 37 (13)
  • [39] Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis
    Benaicha, Karima
    Khenhrani, Raja Ram
    Veer, Maha
    Devi, Sapna
    Shahbaz, Usman
    Salah, Qais M.
    Hammad, Mostafa
    Palleti, Sujith K.
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (05)
  • [40] Clinical Pathways When Considering Antimicrobials for the Treatment of Mild-to-Moderate COVID-19
    Krauth, Daniel S.
    [J]. MILITARY MEDICINE, 2022, 187 (7-8) : 186 - 188